Compare Icl Group Ltd (ICL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs ResMed Inc. — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.65B), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 4.3× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.77%). Which is the better fit depends on your goals.
| ICL | RMD | |
|---|---|---|
Market Cap | $6.65B | $28.81B |
Sector | Basic Materials | Health |
52-Week High | $7.03 | $293.73 |
52-Week Low | $4.80 | $182.82 |
Enterprise Value | $9.22B | $27.99B |
Dividend Yield | 3.77% | 1.21% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
